Current filters:


1 to 9 of 12 results

Genzyme Framingham plant now cleared by US and EU regulators


French drug major Sanofi (Euronext: SAN) said yesterday that the US Food and Drug Administration has…

BiotechnologyFabrazymeGenzymePharmaceuticalRare diseasesRegulationSanofi

Ongoing supply problems for Genzyme’s Cerezyme


US biotech Genzyme, now a subsidiary of French drug major Sanofi (Euronext: SAN), says it will have only…

BiotechnologyCerezymeFabrazymeGenzymeMarkets & MarketingPharmaceuticalRare diseasesSanofiShire

Shire says Fabry and Gaucher disease studies continue to support patient switches to Replagal and Vpriv


Ireland-headquartered specialty drug firm Shire (LSE: SHP) reported positive data from several studies…

CerezymeFabrazymeGenzymePharmaceuticalRare diseasesReplagalResearchSanofiShireVpriv

Genzyme’s 2nd-qtr 2010 profits plunge on continuing Cerezyme and Fabrazyme supply problems


Troubled US biotechnology firm Genzyme yesterday revealed that net profit for the second quarter of 2010…


Genzyme signs consent decree with US FDA to correct violations at manufacturing plant and give up $175 million in profits


Troubled US biotechnology firm Genzyme has signed a consent decree agreeing to correct manufacturing…

BiotechnologyCerezymeFabrazymeFinancialGenzymeNorth AmericaPharmaceuticalRare diseasesRegulationThyrogen

US FDA to take enforcement action regarding Genzyme’s Allston plant, including financial penalties


In another setback for the troubled biotechnology firm, the US Food and Drug Administration has notified…

BiotechnologyCerezymeFabrazymeFinancialGenzymeMyozymeNorth AmericaPharmaceuticalRare diseasesRegulationThyrogen

1 to 9 of 12 results

Back to top